Major Indian hospital chains reported double-digit revenue and EBITDA growth for fiscal year 2026, driven by higher patient volumes and complex medical treatments. While the hospital and diagnostics sectors show strong momentum, medical device manufacturers are navigating challenges from rising raw material costs and international tariff pressures.
Detailed Coverage
India’s healthcare sector closed the 2026 fiscal year with strong performance, led primarily by large-scale hospital networks and organized diagnostics providers. Major hospital chains recorded year-on-year revenue and operating profit, or EBITDA, growth exceeding 15 per cent. This financial expansion was supported by steady hospital occupancy rates, which ranged between 60 per cent and 75 per cent throughout the year, alongside a notable rise in the average income generated per occupied bed.
Specialty Care And Diagnostics Performance
The growth in the hospital segment was heavily influenced by high-acuity medical specialties. Cardiology and oncology departments reported growth rates surpassing 15 per cent, becoming increasingly important contributors to total hospital revenue. Simultaneously, the organized diagnostics segment maintained a strong financial position, with providers reporting revenue growth above 15 per cent and operating profit margins consistently remaining above 25 per cent. This sector has been supported by continuous capital spending on expanding laboratory networks and increasing the number of sample collection points across the country.
Investment Trends And Market Outlook
Investor interest in the healthcare space remained high throughout FY26. Although there was a minor, temporary dip in transaction volumes during the final quarter, private equity activity remained robust. This sustained interest has contributed to higher valuations across the sector. Looking toward FY27, deal activity is expected to remain focused on strategic acquisitions within the hospital space, as well as further investment in integrated diagnostics platforms and digital health infrastructure.
Challenges In The Medical Device Segment
While hospitals and diagnostics have thrived, other parts of the healthcare ecosystem face specific pressures. Manufacturers of medical devices have reported that rising raw material costs and new tariffs on exports to the United States have created difficulties. These factors have put pressure on profit margins for companies involved in device manufacturing, distinct from the service-oriented hospital and diagnostic businesses. Investors should track whether companies in the service segment can continue to manage rising operational costs while maintaining these growth rates, and monitor how device manufacturers adjust to the changing international trade environment in the coming quarters.